Article Sidebar

pdf
Date Published: 30/08/2023
Abstract Views: 197
Views pdf: 122
DOI: https://doi.org/10.51298/vmj.v529i1B.6416
Issue
Vol. 529 No. 1B (2023)
Section
Các bài báo
How to Cite
Mai, T. H. Q., Bùi, V. Q., Trịnh, L. H., & Lê, T. L. Q. (2023). RESULTS OF AFATINIB AS FIRST – LINE TREATMENT OF STAGE IV NON-SMALL CELL LUNG CANCER WITH EGFR MUTATION AT THE HANOI ONCOLOGY HOSPITAL. Vietnam Medical Journal, 529(1B). https://doi.org/10.51298/vmj.v529i1B.6416

RESULTS OF AFATINIB AS FIRST – LINE TREATMENT OF STAGE IV NON-SMALL CELL LUNG CANCER WITH EGFR MUTATION AT THE HANOI ONCOLOGY HOSPITAL

Thị Hồng Quỳnh Mai1,, Vinh Quang Bùi1, Lê Huy Trịnh2, Thị Lệ Quyên Lê1
1 Hanoi Oncology Hospital
2 HMU

Main Article Content

Abstract

Objects: To evaluate the results of Afatinib as first-line treatment of stage IV non-small cell lung cancer with EGFR mutation. Subjects and methods:  A case series study was conducted in 48 patients with EGFR mutation- positive stage IV non-small cell lung cancers that were treated with Afatinib in first-line treatment at the Hanoi Oncology Hospital from 1/2019 to 6/2022. Results: In a total of 48 patients participating in the study, Complete response (CR) to afatinib was 2,1%, Partial Response (PR) was 72,9%; Disease Control Rate (DCR) was 95.8% and there was a relationship between ECOG performance status and the response rate (p<0.05). Median progression-free survival (PFS) was 12 months. Conclusion: First-line treatment of stage IV non-small cell lung cancer patients with EGFR mutations with Afatinib gives a high response rate and improves progression-free survival.

Article Details

Keywords

Non-small cell lung cancer, EGFR mutation, Afatinib

References

H. Sung, J. Ferlay, R. L. Siegel và cộng sự (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin, 71 (3), 209-249.
2. D. S. Ettinger, D. E. Wood, D. L. Aisner và cộng sự (2021). NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021. J Natl Compr Canc Netw, 19 (3), 254-266.
3. James Chih-Hsin Yang, Martin H. Schuler, Nobuyuki Yamamoto và cộng sự (2012). LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. Journal of Clinical Oncology, 30 (18_suppl), LBA7500-LBA7500.
4. Yi Long Wu, Caicun Zhou, Cheng-Ping Hu và cộng sự (2013). LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung. Journal of Clinical Oncology, 31 (15_suppl), 8016-8016.
5. K. Park, E. H. Tan, K. O'Byrne và cộng sự (2016). Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol, 17 (5), 577-589.
6. Nguyễn Văn Việt (2020). Kết quả điều trị bước một ung thư phổi không tế bào nhỏ giai đoạn tiến xa có đột biến EGFR bằng thuốc ức chế tyrosine kynase thế hệ 2 afatinib, Luận văn Thạc sỹ Y học, Trường Đại học Y Hà Nội.
7. Trịnh Lê Huy và Trần Đình Anh (2022). Đánh giá hiệu quả điều trị bước một ung thư phổi không tế bào nhỏ giai đoạn muộn có đột biến EGFR bằng afatinib. Tạp chí Nghiên cứu Y học, 155 (7), 75-83.
8. T. H. Vu, H. T. T. Nguyen, L. K. Dao và cộng sự (2021). Effectiveness and Tolerability of First-Line Afatinib for Advanced EGFR-Mutant Non-Small Cell Lung Cancer in Vietnam. Asian Pac J Cancer Prev, 22 (5), 1581-1590.
9. Võ Thị Huyền Trang và Phạm Cẩm Phương (2021). Đánh giá kết quả afatinib điều trị ung thư phổi không tế bào nhỏ giai đoạn IIIB-IV có đột biến EGFR. Tạp chí Y học Việt Nam, 508 (1), 346-352.